

6<sup>th</sup> November, 2023

- |  |  |
|--|--|
| <p>(1) BSE Ltd<br/>Listing Department<br/>Phiroze Jeejeebhoy Towers,<br/>Dalal Street,<br/>Mumbai - 400 001</p> <p><b>Scrip Code: 500087</b></p> | <p>(2) National Stock Exchange of India Ltd<br/>Listing Department<br/>Exchange Plaza, 5<sup>th</sup> floor,<br/>Plot no. C/1, G Block,<br/>Bandra Kurla Complex, Bandra (East),<br/>Mumbai - 400 051</p> <p><b>Scrip Code: CIPLA EQ</b></p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG<br/>Societe Anonyme<br/>35A Boulevard Joseph II,<br/>L-1840 Luxembourg</p>                             |  |

**Sub: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)**

Dear Sir / Madam,

Pursuant to the provisions of Regulation 30 of the SEBI Listing Regulations, we hereby notify that the Board of Directors of Cipla Limited (“the Company”) at its meeting held today, i.e., 6<sup>th</sup> November, 2023 have inter alia, approved the transfer of Generics Business Undertaking as a going concern on a slump sale basis to Cipla Pharma and Life Sciences Limited (CPLS), a wholly owned subsidiary of the Company.

The details, as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13<sup>th</sup> July, 2023 is enclosed as Annexure – I and II.

Thanking you,

Yours faithfully,  
**For Cipla Limited**

**Rajendra Chopra**  
**Company Secretary**

**Cipla Ltd.**

**Regd. Office** –Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400013, India.

**P** +91 22 24826000 **F** +91 22 24826120 **W** www.cipla.com **E-Mail** contactus@cipla.com **Corporate Identity Number** L24239MH1935PLC002380

**Annexure – I**

**Disclosure of information under SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated  
13<sup>th</sup> July, 2023**

Sr. No	Particulars	Disclosure												
1	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year;	<p>On a standalone basis as on 31<sup>st</sup> March, 2023 (in INR crs)</p> <table border="1"> <thead> <tr> <th>Particulars</th> <th>Cipla Limited</th> <th>Gx business undertaking</th> <th>%</th> </tr> </thead> <tbody> <tr> <td><b>Turnover</b></td> <td>14,519</td> <td>1,445</td> <td>9.95</td> </tr> <tr> <td><b>Net-worth</b></td> <td>24,632</td> <td>227</td> <td>0.92</td> </tr> </tbody> </table>	Particulars	Cipla Limited	Gx business undertaking	%	<b>Turnover</b>	14,519	1,445	9.95	<b>Net-worth</b>	24,632	227	0.92
Particulars	Cipla Limited	Gx business undertaking	%											
<b>Turnover</b>	14,519	1,445	9.95											
<b>Net-worth</b>	24,632	227	0.92											
2	Date on which the agreement for sale has been entered into	<p>The Board of Directors of the Company at its meeting held today i.e., 6<sup>th</sup> November, 2023, have approved the transfer of Generic (Gx) Business Undertaking to Cipla Pharma and Life Sciences Limited (“CPLS”).</p> <p>Business transfer agreement (“BTA”) is yet to be executed. The transaction is subject to the approval of the Board of Directors of CPLS.</p>												
3	The expected date of completion of sale/disposal	Effective date for completion of transfer to CPLS would be end of business hours of 31 <sup>st</sup> December, 2023, or such other date mutually agreed between the parties.												
4	Consideration received from such sale/disposal;	<p>INR 350 crores.</p> <p><i>[The final consideration is subject to the adjustments, if any, as on the date of transfer as per the terms of BTA ]</i></p>												
5	Brief details of buyers and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof;	CPLS is a wholly owned subsidiary of the Company and does not belong to the Promoter / Promoter Group.												
6	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arms-length.	Yes, the transaction is a related party transaction. Since the transaction is between the holding company and its wholly owned subsidiary and the entire economic value of the wholly owned subsidiary following the transfer of the undertaking will remain with the holding company, the arm’s length principle is not relevant.												
7	Name of the entity(ies) forming part of the	Provided below in Annexure II.												

	slumpasale, details in brief such as, size, turnover etc.;	
8	Area of business of the entity(ies);	Provided below in Annexure II.
9	Rationale for slump sale	<p>The generic market is expected to grow at a fast pace and the Company is one of the largest players in Generics Business.</p> <p>With an endeavour to provide agility, singular focus and faster decision making, the Company is transferring its Generics Business Undertaking to Cipla Pharma and Life Sciences Limited, wholly owned subsidiary of the Company. The transaction will help in capitalising on this high growth potential business by increasing investments in new launches, deepening penetration in Tier 2-6 towns/cities and improving patient access through high quality Generic medicines.</p>
10	In case of cash consideration – amount or otherwise share exchange ratio	Cash consideration as specified in point (4) above.
11	Brief details of change in shareholding pattern (if any) of listed entity.	There will not be any change in the shareholding pattern of the Company pursuant to the slump sale.

**Annexure II**

	<b>Cipla Limited</b>	<b>CPLS</b>
Brief Details	Cipla Limited is a public limited company incorporated on 17 <sup>th</sup> August 1935 under the Indian Companies Act, 1913 having CIN L24239MH1935PLC002380 and registered office at Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai, MH – 400013.	Cipla Pharma and Life Sciences Limited (CPLS) is a public limited company incorporated on 20 <sup>th</sup> August 2008 under the Indian Companies Act, 1956 having CIN U24239MH2008PLC381559 and registered office at Tower A, 1 <sup>st</sup> floor, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai, MH – 400013.
Turnover as on 31 <sup>st</sup> March 2023 (in INR crs)	14,519	15
Net-worth as on 31 <sup>st</sup> March 2023 (in INR crs)	24,632	98
Area of business	Cipla Limited is primarily engaged in business of research & development, distribution, marketing and manufacturing of pharmaceutical products.	CPLS is primarily engaged in the business of research & development, distribution, marketing and manufacturing of pharmaceutical products.